Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022
bởiRoshini Claire Anthony
The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.
11 Dec 2022

Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
10 Dec 2022
bởiTristan Manalac
Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).
10 Dec 2022







